Ionis Pharmaceuticals Director Michael Hayden Purchases $1.1 Million Worth of Shares
Michael R. Hayden, director at Ionis Pharmaceuticals (NASDAQ: IONS), purchased 20,000 shares for a total value of $1.1 million between July 30 and July 31, 2026. The purchase price ranged from $51.45 to $53.58 per share with an average weighted cost of $52.94. This transaction increased Hayden's holdings in the company from 58,298 shares to a total of 78,298 shares across both direct and indirect ownership. Ionis Pharmaceuticals has a market capitalization of approximately $8.8 billion as of July 30, 2026, with trailing twelve-month revenue at $873.8 million but also reporting a net loss of $564.8 million over the same period due to significant R&D investments. The company is focused on RNA-targeted therapies and has commercial products such as Spinraza for spinal muscular atrophy. The insider purchase may signal confidence in Ionis Pharmaceuticals' long-term prospects, particularly given its ongoing development of precision medicines targeting rare genetic diseases.
Tickers: $IONS
Topics: insider buying SEC Form 4 stock purchase